Adcirca and Occlusion - renal artery - a phase IV clinical study of FDA data

Summary:

Occlusion - renal artery is reported only by a few people who take Adcirca.

The phase IV clinical study analyzes which people take Adcirca and have Occlusion - renal artery. It is created by eHealthMe based on reports of 51,667 people who have side effects while taking Adcirca from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Dec, 06, 2022

51,667 people reported to have side effects when taking Adcirca.
Among them, 4 people (0.01%) have Occlusion - renal artery.


What is Adcirca?

Adcirca has active ingredients of tadalafil. It is often used in pulmonary hypertension. eHealthMe is studying from 51,715 Adcirca users for its effectiveness, alternative drugs and more.

What is Occlusion - renal artery?

Occlusion - renal artery (a blockage of the major arteries that supply blood to the kidneys) is found to be associated with 1,225 drugs and 704 conditions by eHealthMe.

Number of Adcirca and Occlusion - renal artery reports submitted per year:

Could Adcirca cause Occlusion - renal artery?

Gender of people who have Occlusion - renal artery when taking Adcirca *:

  • female: 25 %
  • male: 75 %

Age of people who have Occlusion - renal artery when taking Adcirca *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

Common drugs people take besides Adcirca *:

  1. Letairis: 4 people, 100.00%

Common side effects people have besides Occlusion - renal artery *:

  1. Haemorrhage (bleeding): 3 people, 75.00%
  2. Cardiac Failure Congestive: 3 people, 75.00%
  3. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 3 people, 75.00%
  4. Swelling: 1 person, 25.00%
  5. Pulmonary Oedema (fluid accumulation in the lungs): 1 person, 25.00%
  6. Malignant Hypertension (Arteriolar Nephrosclerosis) (a medical condition where the blood pressure of the patient suddenly reaches extremely high): 1 person, 25.00%
  7. Hypersensitivity: 1 person, 25.00%
  8. Breathing Difficulty: 1 person, 25.00%

Common conditions people have *:

  1. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 1 person, 25.00%
  2. Left Ventricular End-Diastolic Pressure Increased: 1 person, 25.00%
  3. High Blood Pressure: 1 person, 25.00%
  4. Arterial Stenosis (abnormal narrowing of the aortic valve in the heart): 1 person, 25.00%

* Approximation only. Some reports may have incomplete information.

Do you take Adcirca and have Occlusion - renal artery?

Check whether Occlusion - renal artery is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

How severe was Occlusion - renal artery and when was it recovered:

Expand to all the drugs that have ingredients of tadalafil:

Alternative drugs to, pros and cons of Adcirca:

Common Adcirca side effects:

Browse all side effects of Adcirca:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Occlusion - renal artery treatments and more:

COVID vaccines that are related to Occlusion - renal artery:

Common drugs associated with Occlusion - renal artery:

All the drugs that are associated with Occlusion - renal artery:

Common conditions associated with Occlusion - renal artery:

All the conditions that are associated with Occlusion - renal artery:

How the study uses the data?

The study uses data from the FDA. It is based on tadalafil (the active ingredients of Adcirca) and Adcirca (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: